Moderna and Delta pullback levels draw focus as traders assess healthcare and airline risk

Moderna and Delta pullback levels draw focus as traders assess healthcare and airline risk
Moderna & Delta: Pullback Risk

With both stocks retreating from recent highs, investors are reassessing how far the latest pullbacks can run before longer-term uptrends come under pressure. Moderna remains tied to enthusiasm around its cancer vaccine pipeline, while Delta is contending with recurring swings in fuel-driven sentiment despite steady operating performance.

Highlights

  • Moderna shares fell 17% from a $281 peak to $223 after management reiterated a 2026 filing for intismeran and warned on growth assumptions.
  • Delta Air Lines reported record Q3 adjusted revenue of $17.6 billion, 16% higher on flat capacity, guiding full-year EPS between $5.10 and $5.60 despite a $6 billion fuel cost increase.
  • Moderna's Q3 revenue grew 29% to $1.31 billion with year-end cash guidance of $8.1 to $8.3 billion, supporting its evolution beyond Covid-19 vaccines.

Key support levels for Moderna and Delta

As reported by CNBC, the latest review from Josh Brown and Sean Russo examines two names on their "Best Stocks in the Market" list that are now testing support after strong advances, Moderna and Delta Air Lines.

For Moderna, the rally still rests on investor optimism around oncology, particularly after Moderna and Merck said on Aug. 19 that their personalized cancer vaccine candidate, intismeran, combined with Keytruda, reduced the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Shares have climbed sharply since the stock joined the list in late June, although management's Analyst Day update triggered a 7% drop after executives reiterated a 2026 filing plan for intismeran and warned that 15% to 25% vaccine business growth should not be used as a standing assumption going forward.

Brown says Moderna's recent decline has brought the stock back toward technical levels that matter more for risk control. The shares peaked at $281 on Nov. 9 and then fell 17% in four sessions to Friday's close at $223, with the 50-day moving average rising near $202 and the 200-day near $96. He identifies $202 as a trader stop and $180 as a longer-term investor anchor, arguing that a close below the 50-day would suggest the retreat is becoming more than a normal pullback.

Delta's setup is less convincing in the near term, in Brown's view, after the stock gave back a breakout above its prior range. The airline's shares rallied to $93 within a week of breaking out on Nov. 4, then slipped back to close Friday at $86, near the top of the old trading band that had held between $74 and $86 through September and October.

Brown says a move back above $90 would improve the case for a fresh entry in Delta, with $93 and then the $95 to $96 zone as the next hurdles. He places a trader stop at $80 and points longer-term investors to $74, the Oct. 20 low, as the key downside marker that would signal the range has broken lower on a weekly closing basis.

Fundamentals keep both stories in play

Moderna's underlying business metrics are also improving alongside the stock's oncology narrative. Third-quarter revenue rises 29% to $1.31 billion, the company returns to a 38 cent-per-share profit from a 51 cent-per-share loss a year earlier, and management lifts 2026 revenue growth guidance to 15% to 25% from "up to 10%." It also lowers expected 2026 cash costs to about $3.8 billion and says year-end cash and investments should finish between $8.1 billion and $8.3 billion.

Those figures support the market's view that Moderna is evolving beyond its earlier identity as a Covid-19 vaccine maker. Brown also points to comments from president Stephen Hoge, who describes the company's broader ambition as using mRNA science to build personalized medicines tailored to patients' genetic profiles and disease risks.

Delta's core operations are also holding up even as fuel costs continue to drive volatility in the shares. The airline reports record adjusted third-quarter revenue of $17.6 billion, up 16% on flat aircraft capacity, while adjusted earnings per share edge up to $1.72 from $1.70 a year earlier despite a 62% jump in adjusted fuel expense to $4.1 billion. Premium and loyalty revenue each grow 18% from a year earlier.

For the fourth quarter, Delta guides for revenue growth near 20% and earnings per share of $1.15 to $1.65, based on fuel prices of about $4.25 a gallon. Full-year guidance calls for earnings per share of $5.10 to $5.60, roughly $2.5 billion in free cash flow and more than $2 billion of debt reduction, even as the carrier absorbs a $6 billion year-over-year increase in fuel costs.

The review also notes that an FAA grounding of all flights in the U.S. on Friday night disrupted hundreds of flights, but Delta shares show little reaction at Monday's open. That muted move suggests investors remain more focused on fuel trends and earnings durability than on a one-off operational shock.

We have also discussed the broader context around Moderna support zone near $217.7 as healthcare rotation buoyed sentiment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.